ArticleBone marrow transplantation2013
CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.
Article in Bone marrow transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 89 citations in OpenAlex.
- Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study.Stem cell research & therapy · 2018Trial
- Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.Bone marrow transplantation · 2017Trial
- Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.Bone marrow transplantation · 2015Trial
- Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Article
- Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.Cell reports. Medicine · 2025Article
- Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.Haematologica · 2025Article
- Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis.Frontiers in cellular and infection microbiology · 2025Article
- NK- and T-cell repertoire is established early after allogeneic HSCT and is imprinted by CMV reactivation.Blood advances · 2024Article
- The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.Annals of hematology · 2024Article
- Effect of Cytomegalovirus on the Immune System: Implications for Aging and Mental Health.Current topics in behavioral neurosciences · 2023Article
- Natural killer cells- from innate cells to the discovery of adaptability.Frontiers in immunology · 2023Review
- Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation.International journal of medical sciences · 2023Article
- Cytomegalovirus infection is associated with rapid NK differentiation and reduced incidence of relapse in HLA matched sibling donor transplant patients.Clinical and experimental immunology · 2022Article
- Article
- Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG.Blood advances · 2022Article
- CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoire.Frontiers in immunology · 2022Article
- A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation.Frontiers in cellular and infection microbiology · 2022Article
- Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Preemptive therapy at CMV reactivation has diminished post-transplant CMV mortality. Furthermore, recent studies suggest a favorable 'virus-versus-leukemia' effect from reactivating CMV, reducing relapse of AML after SCT. We studied the relationship of CMV reactivation with leukemic relapse in 110 patients with CML receiving HLA-identical sibling SCT between 1993 and 2008. Of these, 79 (72%) were in chronic phase, 5 in second chronic phase, 17 in accelerated phase and 9 in blast phase. A total of 97 patients (88%) received a myeloablative conditioning regimen, 97 received 4-log ex vivo T cell-depleted grafts and 13 received T-replete grafts. CMV reactivation before day 100 was observed in 72 patients (65.5%). At a median follow-up of 6.2 years, CMV reactivation < day 100 as a time-dependent covariate was an independent factor associated with decreased relapse. We conclude that CMV reactivation may contribute to a beneficial GVL effect in CML transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.